238 related articles for article (PubMed ID: 32888218)
1. Cancer immunotherapy harnessing γδ T cells and programmed death-1.
Tanaka Y
Immunol Rev; 2020 Nov; 298(1):237-253. PubMed ID: 32888218
[TBL] [Abstract][Full Text] [Related]
2. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
[TBL] [Abstract][Full Text] [Related]
3. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.
Tanaka Y; Murata-Hirai K; Iwasaki M; Matsumoto K; Hayashi K; Kumagai A; Nada MH; Wang H; Kobayashi H; Kamitakahara H; Okamura H; Sugie T; Minato N; Toi M; Morita CT
Cancer Sci; 2018 Mar; 109(3):587-599. PubMed ID: 29288540
[TBL] [Abstract][Full Text] [Related]
4. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
Hodgins NO; Wang JT; Al-Jamal KT
Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
Tanaka Y; Iwasaki M; Murata-Hirai K; Matsumoto K; Hayashi K; Okamura H; Sugie T; Minato N; Morita CT; Toi M
Sci Rep; 2017 Jul; 7(1):5987. PubMed ID: 28729550
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract][Full Text] [Related]
7. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
Kimura S
Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
Front Immunol; 2020; 11():1405. PubMed ID: 32793196
[TBL] [Abstract][Full Text] [Related]
9. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.
Umeyama Y; Taniguchi H; Gyotoku H; Senju H; Tomono H; Takemoto S; Yamaguchi H; Tagod MSO; Iwasaki M; Tanaka Y; Mukae H
Front Immunol; 2023; 14():1058838. PubMed ID: 37006249
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
11. Gamma-delta (γδ) T cells: friend or foe in cancer development?
Zhao Y; Niu C; Cui J
J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of pyrophosphate-containing compounds that stimulate Vgamma2Vdelta2 T cells: application to cancer immunotherapy.
Tanaka Y; Kobayashi H; Terasaki T; Toma H; Aruga A; Uchiyama T; Mizutani K; Mikami B; Morita CT; Minato N
Med Chem; 2007 Jan; 3(1):85-99. PubMed ID: 17266628
[TBL] [Abstract][Full Text] [Related]
13. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
14. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
[TBL] [Abstract][Full Text] [Related]
15. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
17. γδ T-cell immunotherapy for lung cancer.
Yoshida Y; Nakajima J; Wada H; Kakimi K
Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates.
Mizuta S; Tagod MSO; Iwasaki M; Nakamura Y; Senju H; Mukae H; Morita CT; Tanaka Y
ChemMedChem; 2019 Feb; 14(4):462-468. PubMed ID: 30637982
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
20. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]